IL106998D0 - Brain-enhanced delivery of neuroactive peptides by sequential metabolism - Google Patents

Brain-enhanced delivery of neuroactive peptides by sequential metabolism

Info

Publication number
IL106998D0
IL106998D0 IL106998A IL10699893A IL106998D0 IL 106998 D0 IL106998 D0 IL 106998D0 IL 106998 A IL106998 A IL 106998A IL 10699893 A IL10699893 A IL 10699893A IL 106998 D0 IL106998 D0 IL 106998D0
Authority
IL
Israel
Prior art keywords
brain
enhanced delivery
neuroactive peptides
sequential metabolism
metabolism
Prior art date
Application number
IL106998A
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US94606292A priority Critical
Application filed by Univ Florida filed Critical Univ Florida
Publication of IL106998D0 publication Critical patent/IL106998D0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/559Redox delivery systems, e.g. dihydropyridine pyridinium salt redox systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/70Enkephalins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0821Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C07K5/0823Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1005Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1024Tetrapeptides with the first amino acid being heterocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
IL106998A 1992-09-17 1993-09-13 Brain-enhanced delivery of neuroactive peptides by sequential metabolism IL106998D0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US94606292A true 1992-09-17 1992-09-17

Publications (1)

Publication Number Publication Date
IL106998D0 true IL106998D0 (en) 1993-12-28

Family

ID=25483900

Family Applications (1)

Application Number Title Priority Date Filing Date
IL106998A IL106998D0 (en) 1992-09-17 1993-09-13 Brain-enhanced delivery of neuroactive peptides by sequential metabolism

Country Status (10)

Country Link
US (1) US5624894A (en)
EP (1) EP0661986B1 (en)
AT (1) AT181081T (en)
AU (1) AU694094B2 (en)
CA (1) CA2144773A1 (en)
DE (2) DE69325279D1 (en)
ES (1) ES2136130T3 (en)
GR (1) GR3031345T3 (en)
IL (1) IL106998D0 (en)
WO (1) WO1994006450A1 (en)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5770085A (en) * 1991-06-12 1998-06-23 Idaho Research Foundation, Inc. Extraction of metals and/or metalloids from acidic media using supercritical fluids and salts
DE19512484A1 (en) 1995-04-04 1996-10-17 Bayer Ag Carbohydrate-modified cytostatics
DE19616486C5 (en) 1996-04-25 2016-06-30 Royalty Pharma Collection Trust A method for lowering blood glucose levels in mammals
US20020006899A1 (en) * 1998-10-06 2002-01-17 Pospisilik Andrew J. Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
US20030176357A1 (en) * 1998-10-06 2003-09-18 Pospisilik Andrew J. Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
US5792357A (en) * 1996-07-26 1998-08-11 Idaho Research Foundation, Inc. Method and apparatus for back-extracting metal chelates
US20020025933A1 (en) * 1996-08-30 2002-02-28 Knudsen Liselotte Bjerre GLP-2 derivatives
AR010744A1 (en) * 1996-12-09 2000-07-12 Guildford Pharmaceuticals Inc polipropilos cyclophilin inhibitors
WO1999012572A1 (en) * 1997-09-10 1999-03-18 University Of Florida Compounds and method for the prevention and treatment of diabetic retinopathy
DE19823831A1 (en) * 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim New pharmaceutical use of isoleucyl thiazolidide and its salts
DE19828113A1 (en) * 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs of inhibitors of dipeptidyl peptidase IV
DE19828114A1 (en) * 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Prodrugs of unstable inhibitors of dipeptidyl peptidase IV
DE19834591A1 (en) 1998-07-31 2000-02-03 Probiodrug Ges Fuer Arzneim Use of substances that decrease the activity of dipeptidyl peptidase IV to increase blood sugar levels, e.g. for treating hypoglycemia
DE19926233C1 (en) 1999-06-10 2000-10-19 Probiodrug Ges Fuer Arzneim Production of thiazolidine, useful as pharmaceutical intermediate, comprises reacting hexamethylenetetramine with cysteamine
US7671029B2 (en) * 1999-08-06 2010-03-02 Immupharma Sa Compositions and methods for enhanced pharmacological activity of compositions comprising peptide drug substances
BR0013366A (en) 1999-08-16 2002-07-23 Revaax Pharmaceuticals Llc Methods for treating a behavioral disorder, a human patient, prostate disease, anxiety disorders and cognitive in a human patient afflicted with a condition or disposed to development of a condition distinguished at least in part by the concentration of abnormal extracellular glutamate in the brain or other nervous tissue, behavioral disorder in the human species, canine, feline and equine species and a patient afflicted with or disposed to develop a disease comprising abnormally high concentrations of glutamate in neuronal or levels of tissue high NAALADase in prostate tissue and multiple sclerosis and to enhance cognitive function, formulation and pharmaceutical use of an inhibitor of a peptidase activity linked acidic dipeptidase n-acetylated alpha and a beta-lactam compound
DE19940130A1 (en) * 1999-08-24 2001-03-01 Probiodrug Ges Fuer Arzneim New effectors of dipeptidyl peptidase IV for topical use
CA2383086A1 (en) * 1999-09-08 2001-03-15 Joseph P. Steiner Non-peptidic cyclophilin binding compounds and their use
BR0107933A (en) 2000-01-28 2004-01-06 Procter & Gamble tasty arginine compounds and their uses for cardiovascular health
US20030165481A1 (en) * 2000-02-24 2003-09-04 Hersh Louis B. Amyloid peptide inactivating enzyme to treat Alzheimer's disease
US20030083277A1 (en) * 2000-02-24 2003-05-01 Hersh Louis B. Use of insulin degrading enzyme (IDE) for the treatment of alzheimer's disease in patients
US8003595B2 (en) * 2000-03-01 2011-08-23 Cellectis Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei
US6890905B2 (en) 2001-04-02 2005-05-10 Prosidion Limited Methods for improving islet signaling in diabetes mellitus and for its prevention
EP2266665B1 (en) * 2000-03-31 2016-05-11 Royalty Pharma Collection Trust Method for the improvement of islet signaling in diabetes mellitus and for its prevention
PL213214B1 (en) * 2000-07-21 2013-01-31 Gilead Sciences, Inc. Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
RU2003115614A (en) * 2000-10-27 2004-10-27 Пробиодруг Аг (De) A method of treating neurological and neuropsychological disorders
US7132104B1 (en) 2000-10-27 2006-11-07 Probiodrug Ag Modulation of central nervous system (CNS) dipeptidyl peptidase IV (DPIV) -like activity for the treatment of neurological and neuropsychological disorders
CA2435829A1 (en) 2001-01-25 2002-08-01 Guilford Pharmaceuticals Inc. Trisubstituted carbocyclic cyclophilin binding compounds and their use
US7074893B2 (en) * 2002-06-03 2006-07-11 Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
US20030096748A1 (en) * 2001-06-04 2003-05-22 The Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
US7368421B2 (en) 2001-06-27 2008-05-06 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
US20030130199A1 (en) * 2001-06-27 2003-07-10 Von Hoersten Stephan Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
JP2005504766A (en) * 2001-08-16 2005-02-17 プロバイオドラッグ アーゲー Proline endopeptidase inhibitor, an intracellular signal cascade dependent inositol (1,4,5) triphosphate used to concentration regulating.
US7049286B2 (en) * 2001-08-30 2006-05-23 Diatos, S.A. Insulin conjugates and methods of use thereof
US6844316B2 (en) * 2001-09-06 2005-01-18 Probiodrug Ag Inhibitors of dipeptidyl peptidase I
WO2003020321A2 (en) * 2001-09-06 2003-03-13 Zimmer Robert H Derivatives of pseudo-peptides, their preparation and their biological uses
DE10150203A1 (en) * 2001-10-12 2003-04-17 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitor in treatment of cancer
US7045543B2 (en) 2001-11-05 2006-05-16 Enzrel Inc. Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
PL372316A1 (en) * 2002-02-28 2005-07-11 Prosidion Limited Glutaminyl based dpiv inhibitors
US20030232761A1 (en) * 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
US20040033051A1 (en) * 2002-08-16 2004-02-19 Ip Kiril Kun Wan Method and system for producing and displaying visual presentations which inhibit off-screen duplication
DE60331747D1 (en) * 2002-09-18 2010-04-29 Prosidion Ltd Secondary binding site of dipeptidyl peptidase IV (DP IV)
US20040058876A1 (en) * 2002-09-18 2004-03-25 Torsten Hoffmann Secondary binding site of dipeptidyl peptidase IV (DP IV)
US7411039B2 (en) * 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
US7687625B2 (en) * 2003-03-25 2010-03-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7371871B2 (en) * 2003-05-05 2008-05-13 Probiodrug Ag Inhibitors of glutaminyl cyclase
JP4996926B2 (en) 2004-02-05 2012-08-08 プロビオドルグ エージー New inhibitors of glutaminyl cyclase
CN101837127A (en) * 2003-05-05 2010-09-22 前体生物药物股份公司 Medical use of inhibitors of glutaminyl and glutamate cyclases
US7638638B2 (en) 2003-05-14 2009-12-29 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7470700B2 (en) * 2003-08-13 2008-12-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP1653989B1 (en) 2003-08-14 2009-07-15 Diatos Anti-bacterial composition, especially for controlling gram-negative bacteria, comprising a peptide and an advantageously hydrophobic anti-bacterial agent
JP2007505121A (en) * 2003-09-08 2007-03-08 武田薬品工業株式会社 Dipeptidyl peptidase inhibitors
JP2007513058A (en) * 2003-09-08 2007-05-24 武田薬品工業株式会社 Dipeptidyl peptidase inhibitors
EP1675578B9 (en) * 2003-10-15 2014-06-25 Probiodrug AG Inhibitors of glutaminyl and glutamate cyclases for the treatment of the neurodegenerative diseases fbd and fdd
US20050171112A1 (en) * 2003-11-03 2005-08-04 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
US20100099721A1 (en) * 2003-11-03 2010-04-22 Probiodrug Ag Novel compounds for the treatment of neurological disorders
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
MXPA06010571A (en) * 2004-03-15 2007-02-16 Takeda Pharmaceutical Dipeptidyl peptidase inhibitors.
EP1753730A1 (en) * 2004-06-04 2007-02-21 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US9044503B2 (en) 2004-08-27 2015-06-02 University Of Kentucky Research Foundation Amyloid peptide inactivating enzyme to treat alzheimer's disease peripherally
US8420602B2 (en) * 2004-09-14 2013-04-16 Landon C. G. Miller Endocannabinoid conjugate and a pharmaceutical composition for treatment of neuronal disorders
WO2006068978A2 (en) * 2004-12-21 2006-06-29 Takeda Pharmaceutial Company Limited Dipeptidyl peptidase inhibitors
WO2006085149A2 (en) 2004-12-22 2006-08-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
EA017799B1 (en) * 2006-09-13 2013-03-29 Такеда Фармасьютикал Компани Лимитед Use of 2-[6-(3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl]-4-fluorobenzonitrile
DK1931350T3 (en) * 2005-09-14 2014-02-10 Takeda Pharmaceutical Administration of inhibitors of dipeptidyl peptidase
US20070060529A1 (en) * 2005-09-14 2007-03-15 Christopher Ronald J Administration of dipeptidyl peptidase inhibitors
ES2376351T5 (en) * 2005-09-14 2014-07-15 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase for treating diabetes
TW200745080A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
TW200745079A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
CN102675221A (en) * 2005-09-16 2012-09-19 武田药品工业株式会社 Intermediate in method for preparing pyrimidinedione derivative
WO2007081530A2 (en) * 2006-01-03 2007-07-19 Med Institute, Inc. Endoluminal medical device for local delivery of cathepsin inhibitors
WO2007112368A1 (en) * 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Preparation of (r)-3-aminopiperidine dihydrochloride
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
ES2533463T3 (en) 2006-10-12 2015-04-10 Bhi Limited Partnership Methods, compounds, compositions and delivery vehicles 3-amino-1-propanesulfonic acid
TW200838536A (en) * 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
CA2699169A1 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Therapeutic uses of intermedin 47 and 53 peptides
US20110178024A1 (en) 2008-09-29 2011-07-21 Ben Gurion University Of The Negev Research And Development Authority Amyloid beta-peptides and methods of use thereof
US20100144140A1 (en) * 2008-12-10 2010-06-10 Novellus Systems, Inc. Methods for depositing tungsten films having low resistivity for gapfill applications
KR101167285B1 (en) * 2011-11-18 2012-07-23 에이앤펩주식회사 Niacin-peptides having skin whitening effect and uses thereof
JP6051308B2 (en) * 2013-08-02 2016-12-27 株式会社日立製作所 Solid-liquid separation device, and method
WO2018226992A1 (en) 2017-06-07 2018-12-13 Adrx, Inc. Tau aggregation inhibitors
WO2019036725A2 (en) 2017-08-18 2019-02-21 Adrx, Inc. Tau aggregation peptide inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540564A (en) * 1982-05-18 1985-09-10 University Of Florida Brain-specific drug delivery
EP0222425A3 (en) * 1982-05-18 1988-09-21 University Of Florida Brain-specific drug delivery
US4829070A (en) * 1982-05-18 1989-05-09 University Of Florida Novel redox carriers for brain-specific drug delivery
AU593209B2 (en) * 1984-02-29 1990-02-08 University Of Florida Brain-specific analogues of centrally acting amines
US4888427A (en) * 1987-04-07 1989-12-19 University Of Florida Amino acids containing dihydropyridine ring systems for site-specific delivery of peptides to the brain

Also Published As

Publication number Publication date
GR3031345T3 (en) 1999-12-31
AU5137993A (en) 1994-04-12
AT181081T (en) 1999-06-15
EP0661986A4 (en) 1997-04-23
WO1994006450A1 (en) 1994-03-31
EP0661986A1 (en) 1995-07-12
EP0661986B1 (en) 1999-06-09
AU694094B2 (en) 1998-07-16
US5624894A (en) 1997-04-29
DE69325279T2 (en) 1999-12-16
CA2144773A1 (en) 1994-03-31
DE69325279D1 (en) 1999-07-15
ES2136130T3 (en) 1999-11-16

Similar Documents

Publication Publication Date Title
US5518998C1 (en) Therapeutic preparation for inhalation
GB2269682B (en) Display system
AU689391B2 (en) Cyclic peptide antifungal agents and process for preparation thereof
GB2273660B (en) Drug delivery arrangement
GB2268492B (en) Protein based delivery system
GB2283422B (en) Lymphatic delivery composition
ZA9602553B (en) Interferon solution
GB9206757D0 (en) Novel peptide receptor ligands
AU5869894A (en) Television program delivery system
AU4664993A (en) Methods for enhancing drug delivery with modified saponins
AU3888893A (en) Use of a peptide
IL102204D0 (en) Therapeutic preparations
GB9217331D0 (en) Pharmaceutical compounds
IL108061D0 (en) Inhaler for powderded medications
EP0619322A3 (en) Prolonged delivery of peptides.
AU680858B2 (en) Therapeutic combination containing interferon
AU4583593A (en) Novel medicinal composition
SI0817621T2 (en) Pharmaceutical composition for transdermic delivery
ZA9208511B (en) Peptides
GB9218322D0 (en) Therapeutic agents
GB9210393D0 (en) Therapeutic agents
GB2269176B (en) Peptides
PL304557A1 (en) Pharmaceutical preparation
ZA9308825B (en) Pharmaceutical compositions
GB9222486D0 (en) Therapeutic agents